nach oben

Erschienen in:

19.06.2020 | Original Article

¹⁸F-FDG PET/CT plays a unique role in the management of Takayasu arteritis patients with atypical manifestations

verfasst von: Jiali Fan, Dongmei Wei, Huimin Zhang, Xiaoxin Sun, Jun Cai, Luyun Fan, Jiachen Yu, Wenjun Ma, Lei Song, Xianliang Zhou

Erschienen in: Clinical Rheumatology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

The present study aimed to evaluate the value of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) aiding in diagnosing and evaluating disease activity in Takayasu arteritis (TA) patients with atypical clinical manifestations.

Methods

A retrospective study of 22 TA patients was conducted. All the participants were classified into two groups. Group one including 12 patients, who did not fulfill American College of Rheumatology (ACR) criteria, were diagnosed by modified Ishikawa criteria. Group two involving ten patients, who did not satisfy the modified Ishikawa criteria or ACR criteria, were clinically diagnosed as TA after panel discussion by a combination of clinical data, excluding other diagnoses. PET/CT results were analyzed using quantitative and qualitative metrics. Disease activity was evaluated using the US National Institutes of Health (NIH) criteria.

Results

In group one, nine patients in active stage and two patients in inactive stage had active FDG uptake. One patient in inactive stage had inactive PET/CT results. In group two, five patients in active stage had active FDG uptake and five patients in inactive stage had inactive FDG uptake with SUVmax values of several vascular lesions slightly lower than livermean in each person. The sensitivity of PET/CT scans for evaluating disease activity was 100.0%, specificity was 75.0%, positive predictive value was 87.5%, and negative predictive value was 100.0% compared to NIH criteria.

Conclusions

PET/CT plays a unique role in diagnosing these TA with atypical manifestation and assisting in evaluating disease activity.

Key Points

• Diagnosis of these TA patients with atypical manifestations may be difficult.

• PET/CT plays a unique role in diagnosing these TA patients and assisting in evaluating disease activity.

Nur mit Berechtigung zugänglich

Numano F, Okawara M, Inomata H, Kobayashi Y (2000) Takayasu's arteritis. Lancet 356(9234):1023–1025. https://doi.org/10.1016/s0140-6736(00)02701-xCrossRefPubMed

Misra R (2019) Takayasu arteritis: a distinct syndrome of large vessel vasculitis: a view point by late Professor Paul Bacon. Int J Rheum Dis 22(Suppl 1):49–52. https://doi.org/10.1111/1756-185x.13383CrossRefPubMed

Ishikawa K (1988) Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy. J Am Coll Cardiol 12(4):964–972. https://doi.org/10.1016/0735-1097(88)90462-7CrossRefPubMed

Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54(Suppl):S141–S147. https://doi.org/10.1016/s0167-5273(96)88783-3CrossRefPubMed

Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33(8):1129–1134. https://doi.org/10.1002/art.1780330811CrossRefPubMed

de Souza AW, de Carvalho JF (2014) Diagnostic and classification criteria of Takayasu arteritis. J Autoimmun 48-49:79–83. https://doi.org/10.1016/j.jaut.2014.01.012CrossRefPubMed

Tezuka D, Haraguchi G, Ishihara T, Ohigashi H, Inagaki H, Suzuki J, Hirao K, Isobe M (2012) Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences. JACC Cardiovasc Imaging 5(4):422–429. https://doi.org/10.1016/j.jcmg.2012.01.013CrossRefPubMed

Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 64(11):1720–1729. https://doi.org/10.1002/acr.21750CrossRef

Santhosh S, Mittal BR, Gayana S, Bhattacharya A, Sharma A, Jain S (2014) F-18 FDG PET/CT in the evaluation of Takayasu arteritis: an experience from the tropics. J Nucl Cardiol 21(5):993–1000. https://doi.org/10.1007/s12350-014-9910-8CrossRefPubMed

10.

Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, Malayeri AA, Merkel PA, Novakovich E, Bluemke DA, Ahlman MA (2018) (18) F-Fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol 70(3):439–449. https://doi.org/10.1002/art.40379CrossRefPubMedPubMedCentral

11.

Zhang X, Zhou J, Sun Y, Shi H, Ji Z, Jiang L (2018) (18)F-FDG-PET/CT: an accurate method to assess the activity of Takayasu’s arteritis. Clin Rheumatol 37(7):1927–1935. https://doi.org/10.1007/s10067-017-3960-7CrossRefPubMed

12.

Danve A, O'Dell J (2015) The role of 18F fluorodeoxyglucose positron emission tomography scanning in the diagnosis and management of systemic vasculitis. Int J Rheum Dis 18(7):714–724. https://doi.org/10.1111/1756-185x.12713CrossRefPubMed

13.

Incerti E, Tombetti E, Fallanca F, Baldissera EM, Alongi P, Tombolini E, Sartorelli S, Sabbadini MG, Papa M, De Cobelli F, Mason JC, Gianolli L, Manfredi AA, Picchio M (2017) (18)F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu's arteritis. Eur J Nucl Med Mol Imaging 44(7):1109–1118. https://doi.org/10.1007/s00259-017-3639-yCrossRefPubMed

14.

Stellingwerff MD, Brouwer E, Lensen KJ, Rutgers A, Arends S, van der Geest KS, Glaudemans AW, Slart RH (2015) Different scoring methods of FDG PET/CT in giant cell arteritis: need for standardization. Medicine (Baltimore) 94(37):e1542. https://doi.org/10.1097/md.0000000000001542CrossRef

15.

Bleeker-Rovers CP, Bredie SJ, van der Meer JW, Corstens FH, Oyen WJ (2003) F-18-fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med 61(10):323–329PubMed

16.

Walter MA, Melzer RA, Schindler C, Muller-Brand J, Tyndall A, Nitzsche EU (2005) The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 32(6):674–681. https://doi.org/10.1007/s00259-004-1757-9CrossRefPubMed

17.

Webb M, Chambers A, AL-Nahhas A, Mason JC, Maudlin L, Rahman L, Frank J (2004) The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 31(5):627–634. https://doi.org/10.1007/s00259-003-1429-1CrossRefPubMed

18.

Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120(11):919–929. https://doi.org/10.7326/0003-4819-120-11-199406010-00004CrossRefPubMed

19.

Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn JE, Benhamou Y, Chiche L, Koskas F, Cluzel P, Hachulla E, Messas E, Resche-Rigon M, Cacoub P, Mirault T, Saadoun D (2017) Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation 136(12):1114–1122. https://doi.org/10.1161/circulationaha.116.027094CrossRefPubMed

20.

Fan L, Zhang H, Cai J, Yang L, Liu B, Wei D, Yu J, Fan J, Song L, Ma W, Zhou X, Wu H, Lou Y (2019) Clinical course and prognostic factors of childhood Takayasu’s arteritis: over 15-year comprehensive analysis of 101 patients. Arthritis Res Ther 21(1):31–12. https://doi.org/10.1186/s13075-018-1790-xCrossRefPubMedPubMedCentral

21.

Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M, Nieman LK (2004) The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)in]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing’s syndrome. J Clin Endocrinol Metab 89(5):2214–2221. https://doi.org/10.1210/jc.2003-031812CrossRefPubMed

22.

Cheng Y, Lv N, Wang Z, Chen B, Dang A (2013) 18-FDG-PET in assessing disease activity in Takayasu arteritis: a meta-analysis. Clin Exp Rheumatol 31(1 Suppl 75):S22–S27PubMed

23.

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E (2017) Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18(4):e206–e217. https://doi.org/10.1016/s1470-2045(17)30189-4CrossRefPubMed

24.

Gallamini A, Borra A (2017) FDG-PET scan: a new paradigm for follicular lymphoma management. Mediterr J Hematol Infect Dis 9(1):e2017029. https://doi.org/10.4084/mjhid.2017.029CrossRefPubMedPubMedCentral

25.

Harrison DJ, Parisi MT, Shulkin BL (2017) The role of (18)F-FDG-PET/CT in pediatric sarcoma. Semin Nucl Med 47(3):229–241. https://doi.org/10.1053/j.semnuclmed.2016.12.004CrossRefPubMed

26.

Arnaud L, Haroche J, Malek Z, Archambaud F, Gambotti L, Grimon G, Kas A, Costedoat-Chalumeau N, Cacoub P, Toledano D, Cluzel P, Piette JC, Amoura Z (2009) Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum 60(4):1193–1200. https://doi.org/10.1002/art.24416CrossRefPubMed

27.

Direskeneli H, Aydin SZ, Kermani TA, Matteson EL, Boers M, Herlyn K, Luqmani RA, Neogi T, Seo P, Suppiah R, Tomasson G, Merkel PA (2011) Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 38(7):1471–1479. https://doi.org/10.3899/jrheum.110275CrossRefPubMedPubMedCentral

28.

Lee KH, Cho A, Choi YJ, Lee SW, Ha YJ, Jung SJ, Park MC, Lee JD, Lee SK, Park YB (2012) The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis Rheum 64(3):866–875. https://doi.org/10.1002/art.33413CrossRefPubMed

29.

Karapolat I, Kalfa M, Keser G, Yalçin M, Inal V, Kumanlioglu K, Pirildar T, Aksu K (2013) Comparison of F18-FDG PET/CT findings with current clinical disease status in patients with Takayasu’s arteritis. Clin Exp Rheumatol 31(1 Suppl 75):S15–S21PubMed

30.

Loricera J, Blanco R, Hernandez JL, Martinez-Rodriguez I, Carril JM, Lavado C, Jimenez M, Gonzalez-Vela C, Gonzalez-Gay MA (2015) Use of positron emission tomography (PET) for the diagnosis of large-vessel vasculitis. Rev Esp Med Nucl Imagen Mol 34(6):372–377. https://doi.org/10.1016/j.remn.2015.07.002CrossRefPubMed

31.

Han Q, Liang Q, Kang F, Wang J, Wu Z, Zhu P (2018) An increased major vessel uptake by 18F-FDG-PET/CT in NIH criteria inactive patients with Takayasu’s arteritis. Clin Exp Rheumatol 36(Suppl 111 (2)):88–92PubMed

32.

Soriano A, Pazzola G, Boiardi L, Casali M, Muratore F, Pipitone N, Catanoso M, Aldigeri R, Cimino L, Versari A, Salvarani C (2018) Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu’s and giant cell arteritis using positron emission tomography. Clin Exp Rheumatol 36(Suppl 111 (2)):99–106PubMed

33.

Alibaz-Oner F, Aydin SZ, Direskeneli H (2015) Recent advances in Takayasu’s arteritis. Eur J Rheumatol 2(1):24–30. https://doi.org/10.5152/eurjrheumatol.2015.0060CrossRefPubMedPubMedCentral

34.

Barra L, Kanji T, Malette J, Pagnoux C (2018) Imaging modalities for the diagnosis and disease activity assessment of Takayasu’s arteritis: a systematic review and meta-analysis. Autoimmun Rev 17(2):175–187. https://doi.org/10.1016/j.autrev.2017.11.021CrossRefPubMed

35.

Hong S, Bae SH, Ahn SM, Lim DH, Kim YG, Lee CK, Yoo B (2015) Outcome of Takayasu arteritis with inactive disease at diagnosis: the extent of vascular involvement as a predictor of activation. J Rheumatol 42(3):489–494. https://doi.org/10.3899/jrheum.140981CrossRefPubMed

36.

Goel R, Danda D, Joseph G, Ravindran R, Kumar S, Jayaseelan V, Jayaseelan L, Bacon P (2018) Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching hospital in southern India. Semin Arthritis Rheum 47(5):718–726. https://doi.org/10.1016/j.semarthrit.2017.09.014CrossRefPubMed

37.

Ladapo TA, Gajjar P, McCulloch M, Scott C, Numanoglu A, Nourse P (2015) Impact of revascularization on hypertension in children with Takayasu's arteritis-induced renal artery stenosis: a 21-year review. Pediatr Nephrol 30(8):1289–1295. https://doi.org/10.1007/s00467-015-3049-yCrossRefPubMed

38.

Park HS, Do YS, Park KB, Kim DK, Choo SW, Shin SW, Cho SK, Hyun D, Choo IW (2013) Long term results of endovascular treatment in renal arterial stenosis from Takayasu arteritis: angioplasty versus stent placement. Eur J Radiol 82(11):1913–1918. https://doi.org/10.1016/j.ejrad.2013.06.019CrossRefPubMed

39.

Peng M, Ji W, Jiang X, Dong H, Zou Y, Song L, Zhang H, Zhang W, Yang Y, Gao R (2016) Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis: two-year results. Int J Cardiol 205:117–123. https://doi.org/10.1016/j.ijcard.2015.12.006CrossRefPubMed

Titel: 18F-FDG PET/CT plays a unique role in the management of Takayasu arteritis patients with atypical manifestations
verfasst von: Jiali Fan
Dongmei Wei
Huimin Zhang
Xiaoxin Sun
Jun Cai
Luyun Fan
Jiachen Yu
Wenjun Ma
Lei Song
Xianliang Zhou
Publikationsdatum: 19.06.2020
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 2/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05028-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

¹⁸F-FDG PET/CT plays a unique role in the management of Takayasu arteritis patients with atypical manifestations

Abstract

Objective

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Can therapeutic response to IL-1 blockade confirm the diagnosis of Schnitzler syndrome?

The clinical characteristics of low C4 alone in patients with systemic lupus erythematosus

Cardiac valvular involvement of Takayasu arteritis

Intra-articular injection of etanercept versus glucocorticoids in rheumatoid arthritis patients

Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis—a real-life experience

Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still’s disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin